Vireo Health to Webcast Live at VirtualInvestorConferences.com June 24th

VIEW ALL NEWS

Field Trip Psychedelics Announces New Podcast, Field Tripping: Epic Trips in Psychedelics

TORONTOJune 23, 2020 /PRNewswire/ — Field Trip Psychedelics Inc. (“Field Trip” or the “Company“), the world’s first mental wellness company focused exclusively on psychedelics and psychedelic-enhanced psychotherapy, announced the launch of the podcast Field Tripping: Epic Trips in Psychedelics with Ronan Levy. The podcast will cover psychedelics, the people that use them, industry trends and frequently asked questions. Field Tripping is available on its website (www.fieldtripping.fm) as well as on SpotifyApple Podcasts and Google Podcasts.

The weekly podcast features conversations with celebrities, entrepreneurs, artists, scientists and medical experts about their consciousness expanding experiences on psilocybin, LSD and MDMA, while exploring how psychedelics can shift our views on sex, science, business, fitness, life and death.

The premiere episode features an interview with best selling author Don Lattin of The Harvard Psychedelic Club and Changing Our Minds — Psychedelic Sacraments and the New PsychotherapyRonan Levy speaks to Don about bad trips, the renaissance of psychedelics and the nature of addiction. Upcoming episodes include interviews with other thought leaders advancing the psychedelic movement such as:

  • Alex Ikonn: Co-founder of Intelligent Change Inc. and Co-author of The Five Minute Journal (one of Tim Ferriss’ “Tools of Titans”) and The Productivity Planner
  • Director X: Award winning Producer and Director of Superfly as well as music videos for Drake, Kanye West, Rihanna and Kendrick Lamar. Founder of Operation Prefrontal Cortex, a program harnessing the power for mindfulness and meditation to help reduce gun violence
  • Dr. Andrew Weil: Celebrity physician and author who is credited as being the “Father of Integrative Medicine”
  • Donick Cary: Emmy-winning Writer, Producer, and Director as well as the creator of the hit Netflix series “Have a Good Trip: Adventures in Psychedelics”

“We are seeing a surge of interest in psychedelics from the medical community, investors, and consumers. To help feed this appetite and give people a welcoming and open forum to talk about their experiences, we decided to launch a resource exploring how psychedelics awaken new views on sex, science, business, fitness, life, and death, on a journey with influential and inspiring guests,” said Ronan Levy, Executive Chairman of Field Trip. “We hope this continues to spark widespread interest in the therapeutic benefits of psychedelics and listeners can learn about this rapidly  growing industry.” 

About Field Trip Psychedelics Inc. 
Field Trip is the world’s first mental wellness company at the forefront of the scientific re-emergence of psychedelics and psychedelic-enhanced therapies. With Field Trip Health centres opening across North America, and drug development and advanced research on plant-based psychedelics through Field Trip Discovery, we help people to heal and heighten engagement with the world. Learn more at https://fieldtriphealth.com

SOURCE Field Trip Psychedelics

Related Links

https://fieldtriphealth.com

COVID-19 is Hurting Chronic Migraine Care in Canada

June is National Migraine and Headache Awareness Month

 

TORONTO, June 23, 2020 – Like most chronic conditions, COVID-19 is having an incredible impact on patients living with chronic migraines (CM). Allergan, an AbbVie Company, is proudly supporting National Migraine and Headache Awareness Month encouraging patients and caregivers to share their experiences with #MoreThanAMigraine to encourage dialogue and awareness surrounding chronic migraines, migraines and headaches.

 

“The COVID-19 pandemic has been a particularly vulnerable time for individuals with chronic migraines, with many physical and mental stressors, increased anxiety, and changes in daily routine that have served as triggering factors for worsening symptoms. This, combined with limited access to their headache specialists, has resulted in trying times for this patient population to manage their condition,” said Dr. Ian Finkelstein, Medical Director at the Toronto Headache & Pain Clinic. “Chronic migraine patients ‘walk a tight line’ when it comes to managing their symptoms, and COVID-19 has been an impetus in derailing many otherwise well controlled patients. Better diagnosis, management and education surrounding this disabling condition is of paramount importance.”

 

The Difference Between Migraines and Other Types of Headaches

Migraines are more severe and debilitating than other types of headaches, and impact over 2.7 million Canadians.1 They consist of moderately to severely intense headaches with throbbing or pulsating pain and are often on one side of the head.2 Other debilitating symptoms include nausea; vomiting; and hypersensitivity to lights, sounds and smells.3

 

#MoreThanAMigraine

Throughout June, Allergan is encouraging migraine sufferers to break their silence in hopes to spread awareness on the condition, to highlight the symptoms, and qualify disease impact. Patients and caregivers can share their experiences online using #MoreThanAMigraine. A patient self-assessment, triggers and treatment options can be accessed via mychronicmigraine.ca. The site also features a search tool that allows Canadians to find a doctor in their area who may be able to help. Migraine sufferers should speak to their healthcare providers about their quality of life and symptom impact.

 

Throbbing Statistics

  • It is estimated that between 370,000- 600,000 adult Canadians, 18 years or older, suffer from 4
  • Over 80 per cent of CM sufferers in Canada are women.5

 

  • It has been estimated that just 20.2 per cent of CM sufferers receive a CM diagnosis, and only 3 per cent of CM patients use preventive medication.6
  • Patients with CM are more likely to miss days of work, school, household work, become occupationally disabled and experience lower levels of household 7,8
  • Patients with CM are nearly twice as likely to be affected by depression or anxiety when compared to episodic migraines.9
  • Patients with CM are more likely to receive opioid medications than those with episodic 10,11

 

About AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

-30-

 

Media:

Jennifer Gordon

Head of Communications Allergan, an AbbVie company Jennifer.gordon@allergan.com Tel.: 905-940-7003

 

 

  • Statistics Canada. Prevalence of migraine in the Canadian household population. Accessed May 2018: https://www.statcan.gc.ca/pub/82-003-x/2014006/article/14033- htm
  • Natoli JL et al. Global Prevalence of Chronic Migraine: A Systematic Review. Cephalalgia. 2010 May;30 (5):599-609.. 3 Natoli JL et Global Prevalence of Chronic Migraine: A Systematic Review. Cephalalgia. 2010 May;30 (5):599-609.
  • 4 Natoli JL et Global Prevalence of Chronic Migraine: A Systematic Review. Cephalalgia. 2010 May;30 (5):599-609.
  • Stokes M. et al. “Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS).” American Headache Society. 2011 May: 1065.
  • Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: Burden, diagnosis, and satisfaction with treatment. Neurology. 2008;71:559-566. doi:10.1212/01.wnl.0000323925.29520.e7.
  • Buse DC, Manack A, Serrano D, Turkel C, Lipton RB. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010;81(4):428-432. doi:10.1136/jnnp.2009.192492.
  • Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: Burden, diagnosis, and satisfaction with treatment. Neurology. 2008;71:559-566. doi:10.1212/01.wnl.0000323925.29520.e7.
  • Buse DC, Manack A, Serrano D, Turkel C, Lipton RB. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg 2010;81(4):428-432. doi:10.1136/jnnp.2009.192492.
  • Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: Burden, diagnosis, and satisfaction with treatment. Neurology. 2008;71:559-566. doi:10.1212/01.wnl.0000323925.29520.e7.
  • Pavlovic J, Yu J, Silberstein S, et al. Migraine Treatment Patterns and Opioid Use Among Chronic and Episodic Migraine Patients Identified by a Clinician-Administered Semi-Structured Diagnostic Interview (S32.001). Neurology. 2018;90(15 Supplement):S32.001. http://n.neurology.org/content/90/15_Supplement/S32.001. Accessed June 1,

Vireo Health Announces Sale of Equity in Pennsylvania Medical Solutions to Jushi Holdings Inc. for Total Consideration of $37 Million

– Transaction secures Vireo’s financial future without dilutive impacts to shareholders –
– Purchase price includes $16.3 million in cash and $17 million in future liabilities –
– Jushi receives 18-month option to acquire Equity in Pennsylvania Dispensary Solutions, LLC –

MINNEAPOLIS, June 22, 2020 /PRNewswire/ — Vireo Health International, Inc. (“Vireo” or the “Company”) (CNSX: VREO; OTCQX: VREOF), the science-focused, multi-state cannabis company with active operations in exclusively medical-only markets and licenses in nine states and the Commonwealth of Puerto Rico, today announced that it has reached a definitive agreement with Jushi Inc, a subsidiary of Jushi Holdings, Inc. (“Jushi”) (CSE: JUSH) (OTCQX: JUSHF), to divest equity in its subsidiary company, Pennsylvania Medical Solutions, LLC (“PAMS”), for total consideration of $37 million. The transaction is subject to regulatory approvals.

Vireo Logo (PRNewsfoto/Vireo Health, Inc.)

Pennsylvania Medical Solutions holds a permit for the cultivation and processing of medical cannabis in the state of Pennsylvania. This permit was initially awarded to PAMS through a merit-based application process in 2017. Based in Scranton, PAMS manufactures cannabis-based products in a 90,000 square foot co-located cultivation and processing facility, which recently underwent a significant capacity expansion project in order to meet increasing demand within Pennsylvania’s burgeoning medical cannabis market.

“This transaction secures Vireo’s capital position for the foreseeable future and will enable us to comfortably execute our fiscal year 2020 operating strategy and begin generating positive cash flow in the first half of next year without requiring any additional capital infusions,” said Founder & Chief Executive Officer, Kyle Kingsley, M.D. “We’re especially pleased to achieve this milestone for shareholders without the dilutive impacts of other forms of financing, and we’re also very excited about the opportunities in front of us to re-invest a portion of these proceeds to increase scale in select markets where we see significant opportunities to improve revenue growth and future cash flow generation.”

The transaction’s total consideration of $37 million includes $16.3 million in cash, $3.8 million in the form of a four-year note with an 8 percent coupon rate payable quarterly and $17 million in Right of Use liabilities associated with long-term lease obligations. The transaction also includes an 18-month option for Jushi to purchase equity in another Vireo Health subsidiary, Pennsylvania Dispensary Solutions, LLC, for an additional $5 million in cash.

Vireo management expects to utilize a portion of the transaction proceeds for capital expenditures that will increase scale in its core markets of New York, Minnesota, Maryland, Arizona, and New Mexico. These development projects are expected to significantly improve the Company’s near-term revenue and profitability outlook, and management anticipates discussing these development projects and other impacts of this transaction in more detail during the Company’s upcoming second-quarter earnings conference call in late August.

About Vireo Health International, Inc.

Vireo Health International, Inc. is a physician-led cannabis company focused on building long-term, sustainable value by bringing the best of medicine, science, and engineering to the cannabis industry. With operations strategically located in early-stage, limited-license medical markets, Vireo manufactures pharmaceutical-grade cannabis products in environmentally-friendly greenhouses and distributes its products through its growing network of Green Goods™ retail dispensaries and hundreds of third-party locations. Its current core medical markets of New York, Minnesota, Pennsylvania, Arizona, New Mexico, and Maryland all have the potential to enact adult-use legalization in the next three to 24 months, and two additional markets in Puerto Rico and Massachusetts also have potential for commercialization. Combined with its teams’ focus on driving scientific innovation within the industry and securing meaningful intellectual property, Vireo believes it is well positioned to become a global market leader in the cannabis industry. Today, eight of its 10 markets are operational with 13 of its 32 total retail dispensary licenses open for business. For more information about the company, please visit www.vireohealth.com.

About Jushi Holdings Inc.

Jushi Holdings, Inc. is a globally focused cannabis and hemp company led by an industry leading management team. In the United States, Jushi is focused on building a multi-state portfolio of branded cannabis and hemp-derived assets through opportunistic acquisitions, distressed workouts and competitive applications. Jushi strives to maximize shareholder value while delivering high quality products across all levels of the cannabis and hemp ecosystem. For more information please visit www.jushico.com or the Company’s social media channels on Instagram, Facebook, Twitter and LinkedIn.

Forward-Looking Statement Disclosure

This news release contains “forward-looking information” within the meaning of applicable United States and Canadian securities legislation. To the extent any forward-looking information in this news release constitutes “financial outlooks” within the meaning of applicable United States or Canadian securities laws, such information is being provided as preliminary financial results and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such financial outlooks. Forward-looking information contained in this press release may be identified by the use of words such as “plans,” “expects” or “does not expect,” “is expected,” “look forward to,” “budget” “scheduled,” “estimates,” “forecasts,” “will continue,” “intends,” “anticipates,” “does not anticipate,” “believes,” “should,” “should not,” or variations of such words and phrases or indicates that certain actions, events or results “may,” “could,” “would,” “might,” or “will” “be taken,” “occur,” or “be achieved.”  Forward-looking information may include, without limitation, statements regarding the operations, business, financial condition, expected financial results, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies and outlook of Vireo, and includes statements about, among other things, the value of assets, the amount of liabilities, the designation of certain businesses or assets as “core” or “non-core,” decisions about allocation of capital and other resources, future developments, the future operations, potential market opportunities including the potential effects of the approval of adult-use cannabis in one or more markets, potential opportunities to monetize assets, strengths and strategy of the Company. Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. These statements should not be read as guarantees of future performance or results. Forward-looking information includes statements with respect to the opportunities for the Company to leverage increasing scale to improve sales growth and operating performance; the anticipation that the medical-only state markets in which the Company’s subsidiaries operate could enact recreational-use legislation over the near-to mid-term future; the anticipated benefits of strategic initiatives; the effects of reduction of corporate overhead and SG&A expenses; improvement to unit economics; expansion of retail dispensaries in key markets; and the expectation that such expansion will drive stronger revenue growth, operating margins and free cash flow. Forward-looking information includes both known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release including, without limitation, the impact on the Company’s businesses and financial results of epidemics and pandemics, including the COVID-19 pandemic. Financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to various risks as set out herein. Our actual financial position and results of operations may differ materially from management’s current expectations and, as a result, our revenue and cash on hand may differ materially from the revenue and cash values provided in this news release. Forward-looking information is based upon a number of estimates and assumptions of management, believed but not certain to be reasonable, in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct, including preliminary financial expectations regarding the annualized reduction of corporate overhead and SG&A expenses. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to, risks related to preliminary financial results being subject to the completion of the Company’s financial closing procedures and not being audited or reviewed by the Company’s independent registered public accounting firm; the timing of recreational-use legislation in markets where the Company currently operates; current and future market conditions, including the market price of the subordinate voting shares of the Company; federal, state, local and foreign government laws, rules and regulations, including federal and state laws in the United States relating to cannabis operations in the United States; limited operating history; changes in laws, regulations and guidelines; operational, regulatory and other risks; execution of business strategy; management of growth; difficulty to forecast; conflicts of interest; risks inherent in an agricultural business; liquidity and additional financing; foreign private issuer status and the risk factors set out in the Company’s listing statement dated March 19, 2019, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com.

The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Media Inquiries

Investor Inquiries

Albe Zakes

Sam Gibbons

Vice President, Corporate Communications

Vice President, Investor Relations

albezakes@vireohealth.com

samgibbons@vireohealth.com 

(267) 221-4800

(612) 314-8995

CisionView original content to download multimedia:http://www.prnewswire.com/news-releases/vireo-health-announces-sale-of-equity-in-pennsylvania-medical-solutions-to-jushi-holdings-inc-for-total-consideration-of-37-million-301080799.html

SOURCE Vireo Health International, Inc.

CHAMPIGNON ANNOUNCES REGULATORY REVIEW

VANCOUVER, British Columbia, June 22, 2020 – Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) announces that it has been selected for a continuous disclosure review by the British Columbia Securities Commission (the “Commission”).  The review relates to the Company’s disclosure obligations since it became a reporting issuer on February 6, 2020 and includes a review of the disclosure surrounding certain recent acquisitions completed by the Company.

“With the recent growth and interest in our industry, ensuring our disclosure obligations are satisfied is at the forefront of our attention.  Ensuring fulsome and timely disclosure is vital to the success of our Company, and development of our industry with the investing public.  We look forward to working with staff of the British Columbia Securities Commission to complete their review, and are hopeful that trading will resume as soon as possible,” commented Dr. Roger McIntyre, Chief Executive Officer of the Company.

In connection with the review, the Commission has issued a cease trade order suspending trading in the securities of the Company pending the filing of business acquisition reports by the Company in connection with the acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp.  As a result of the cease trade order, trading in the common shares of the Company has been suspended on the Canadian Securities Exchange.

The Company will fully cooperate with the Commission, to assist in completion of the review and revocation of the cease trade order in a timely fashion.  The Company will provide further information regarding the status of the review, and the suspension of trading, as it becomes available.

ON BEHALF OF THE BOARD OF DIRECTORS

Dr. Roger McIntyre
Chief Executive Officer
E: info@braxiascientific.com

FOR INVESTOR INQUIRIES:

Champignon Brands | Storyboard Communications
Investor Relations, Toronto, Canada
Investor Line:  +1 (833) 375-9995 x611
E: champignonbrands@storyboardcommunications.com

FOR CHAMPIGNON BRANDS FRENCH INQUIRIES:
Remy Scalabrini, Maricom Inc.
E: rs@maricom.ca
T: (888) 585-MARI

The CSE and Information Service Provider have not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. There are no assurances that the business plans for Champignon Brands described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which are available at www.sedar.com.

YIELD GROWTH LAUNCHES SHOPIFY ONLINE STORE TO BOLSTER DIRECT TO CONSUMER SALES

July 22, 2020 – Vancouver, BC: The Yield Growth Corp. (CSE:BOSS) (OTCQB:BOSQF) (FE:YG3(“Yield Growth” or the “Company”) is pleased to announce the launch of its new e-commerce website for subsidiary brand, Urban Juve, powered by leading ecommerce platform, Shopify.

The online store features the complete Urban Juve plant-based collection as well as select other products, such as Antler’s natural deodorant for men and Urban Juve’s hand sanitizers.

The optimized online store offers a seamless browsing and purchase experience, richer and more robust product content, a range of payment options including Paypal and Apple Pay, as well as key post-purchase automations and marketing programs designed to increase repeat sales.

“Launching a refreshed and optimized ecommerce site is a key strategic project for Urban Juve. It not only improves the customers’ experience with our brand, but is a solid platform upon which we can now develop and expand conversion-driven marketing programs such as influencer and affiliate programs, subscription models, and more,” said Karla Cheon, Vice President of Marketing for Yield Growth. “This initiative, combined with web traffic-generation efforts, will provide quality customer data for Urban Juve to nurture its loyal and growing customer base who are seeking plant-based alternatives for their skin.”

The launch of the optimized UrbanJuve.com on Shopify, the launch of Urban Juve on Amazon.ca and the soon to launch Amazon.com listings are key components of the Company’s strategic plan to invest in and grow direct to consumer sales.

The Company is pleased to offer a 15% discount on urbanjuve.com (using code: INVESTOR15) in celebration of the launch, valid until July 31st, 2020.

Shopify has become the second largest online shopping destination second only to Amazon, as reported by The Observer in September 2019.

The U.S. department of commerce reported that retail e-commerce sales for the first quarter of 2020 reached $146.6 billion, an increase of 14.5% when compared to the first quarter of 2019.

Consumers spent $601.75 billion online with U.S. merchants in 2019, up 14.9% from $523.64 billion in 2018, also according to the U.S. Department of Commerce. This is an increase over 2018’s growth, which was up 13.6% from 2017.

 

About The Yield Growth Corp.

The Yield Growth Corp. is a phytoceutical and consumer packaged goods company that develops and acquires intellectual property and other assets related to plant-based products and therapeutics, and develops, manufactures, markets, sells and distributes plant-based products.  It has over 200 proprietary wellness formulas at various stages of commercialization, with over 20 products, including a hand sanitizer, that are now for sale through e-commerce or brick and mortar retail stores.   It has 14 patent applications to protect its extraction methods and wellness formulas and it is in the early stages of research and development of plant based topicals for prevention or treatment of infectious disease.  The Global Wellness Institute reports the global wellness industry is a $4.2 trillion-dollar global wellness market.  Its majority owned subsidiary NeonMind Biosciences Inc. is launching a line of medicinal mushroom products and is developing intellectual property in the emerging area of psychedelic medicine.  The Yield Growth management team has deep experience with global brands including Johnson & Johnson, Procter & Gamble, Skechers and Aritzia.

 

Investor Relations Contacts:

Penny White, President & CEO

Kevan Matheson, Investor Relations

invest@yieldgrowth.com

1-833-514-BOSS   1-833-514-2677

1-833-515-BOSS   1-833-515-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies do to the spread of the Coronavirus, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Yield Growth cautions readers not to place undue reliance on forward-looking statements provided by Yield Growth, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Yield Growth expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

ATAI launches IntroSpect Digital Therapeutics, appoints veteran software engineer David Keene as CEO

LONDON and NEW YORK, June 22, 2020 /PRNewswire/ — Today, ATAI Life Sciences (“ATAI” or the “Company”), a global biotech developing psychedelic and non-psychedelic compounds for various mental health indications, announced the launch of its digital therapeutic platform IntroSpect Digital Therapeutics, Inc. (“IntroSpect”). David Keene, who brings almost two decades of experience in tech- and healthcare-related fields, will serve as CEO and will be leading ATAI’s efforts to bring digital therapeutics (DTx) and precision psychiatry to bear on the mental health epidemic.

”The ubiquity of mental illness mandates that we leverage emerging technologies to improve our ability to support patients wherever they may be,” said Florian Brand, CEO of ATAI Life Sciences. “David’s unique experience will be indispensable to helping us treat the individual rather than the disease.”

Before coming to ATAI, Keene worked as a software engineer and served in leadership roles at a variety of online retail and gaming companies. After a life-changing cancer diagnosis, David felt compelled to found Everystory, which became Dthera Sciences in 2016. As Chief Technology Officer, David led the development of DTHR-ALZ, an artificial intelligence-enabled device for Alzheimer’s disease with text messaging and complex emotional recognition capabilities based on cameras and facial landmark data. The device was one of the first that the FDA granted Breakthrough Device Designation for Alzheimer’s and went from inception to production in just 18 months.

“Using the flexibility and power of digital technology allows us to be more capable than ever of meeting patients on their own terms.” said Keene. ”By using a variety of digital biomarkers, we stand to make treatments increasingly refined, effective, and – most importantly for mental healthcare – individualized.”

ATAI’s DTx initiative will also pair the development of digital tools or devices with concurrent clinical research into certain compounds on the company’s platform to enhance their therapeutic impact, with the goal of delivering personalized and scalable treatments to those who might not otherwise be able to access high quality care. Moreover, by following a modular approach to development, technologies developed for one indication or compound will be more easily repurposed for others being studied by the company.

“With improved understanding of how individual biological phenotypes align with responses to certain interventions, clinicians will be better able to predict patients’ recovery pathways,” said Srinivas Rao, Chief Scientific Officer of ATAI Life Sciences.

“This, in turn, will cut down trial and error and shorten the time to therapeutic impact. And for those with difficult to treat mental illnesses, time is absolutely critical.”

Company Contact:
Allan Malievsky
ATAI Life Sciences
Phone: +1 (917) 974-1371
Email: Allan@ATAI.life

Investor Contact:
Allison Soss
KCSA Strategic Communications
Phone: +1 (212) 896-1267
Email: ATAI@KCSA.com

About ATAI Life Sciences
Founded by visionary entrepreneur Christian Angermayer, ATAI Life Sciences AG is a global biotech platform and company builder working to address significant unmet medical needs rooted in a lack of innovation in neuropsychiatry. Based in Berlin, London and New York, its vision is to cure mental health disorders, enabling people to live healthier and happier lives.

SOURCE ATAI Life Sciences

Vireo Health Expands Maryland Operations with Purchase of 110,000 Sq. Ft. Greenhouse

– $1.3 million cash transaction expands Vireo’s Maryland cultivation capacity by nearly 12x –
– Vireo to transfer cultivation license to new greenhouse; maintain existing processing facility –

MINNEAPOLIS, June 19, 2020 /PRNewswire/ — Vireo Health International, Inc. (“Vireo” or the “Company”) (CNSX: VREO; OTCQX: VREOF), the science-focused, multi-state cannabis company with active operations in exclusively medical-only markets and licenses in nine states and the Commonwealth of Puerto Rico, today announced that its subsidiary company, MaryMed, LLC, has reached a definitive agreement to acquire the assets and operations of Maryland based Goose Landing Farms, Inc., for total consideration of $1.3 million. The transaction is subject to regulatory approval and customary closing conditions.

Vireo Logo (PRNewsfoto/Vireo Health, Inc.)

Goose Landing Farms owns and operates a 110,200 sq. ft. greenhouse facility in Massey, MD which is currently growing perennials. The site also contains an indoor area for post processing. MaryMed intends to transfer its cultivation license in the state to this newly acquired greenhouse and maintain processing and manufacturing operations at its existing 22,000 sq. ft. facility in Hurlock, MD. This planned license transfer is expected to increase MaryMed’s biomass cultivation capacity in the state by nearly 12 times once the transfer of cultivation operations is complete. Vireo anticipates completing its first harvest in the new facility during the upcoming Fall season.

“This acquisition significantly increases our revenue growth potential in Maryland’s attractive medical cannabis market at a relatively low cost, and it will enable us to drive stronger profitability within this market once our retail dispensary license becomes operational,” said Founder & Chief Executive Officer, Kyle Kingsley, M.D. “This transaction is consistent with our objective of increasing scale in our core markets to improve margins and cash flow generation, and we’re looking forward to seeing the benefits of this acquisition on revenue growth and profitability beginning in the fourth quarter of this year.”

About Vireo Health International, Inc.

Vireo Health International, Inc. is a physician-led cannabis company focused on building long-term, sustainable value by bringing the best of medicine, science, and engineering to the cannabis industry. With operations strategically located in early-stage, limited-license medical markets, Vireo manufactures pharmaceutical-grade cannabis products in environmentally-friendly greenhouses and distributes its products through its growing network of Green Goods™ retail dispensaries and hundreds of third-party locations. Its current core medical markets of New York, Minnesota, Pennsylvania, Arizona, New Mexico, and Maryland all have the potential to enact adult-use legalization in the next three to 24 months, and two additional markets in Puerto Rico and Massachusetts also have potential for commercialization. Combined with its teams’ focus on driving scientific innovation within the industry and securing meaningful intellectual property, Vireo believes it is well positioned to become a global market leader in the cannabis industry. Today, eight of its 10 markets are operational with 13 of its 32 total retail dispensary licenses open for business. For more information about the company, please visit www.vireohealth.com.

Forward-Looking Statement Disclosure

This news release contains “forward-looking information” within the meaning of applicable United States and Canadian securities legislation. To the extent any forward-looking information in this news release constitutes “financial outlooks” within the meaning of applicable United States or Canadian securities laws, such information is being provided as preliminary financial results and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such financial outlooks. Forward-looking information contained in this press release may be identified by the use of words such as “plans,” “expects” or “does not expect,” “is expected,” “look forward to,” “budget” “scheduled,” “estimates,” “forecasts,” “will continue,” “intends,” “anticipates,” “does not anticipate,” “believes,” “should,” “should not,” “looking forward to,” or variations of such words and phrases or indicates that certain actions, events or results “may,” “could,” “would,” “might,” or “will” “be taken,” “occur,” or “be achieved.”  Forward-looking information may include, without limitation, statements regarding the operations, business, financial condition, expected financial results, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies and outlook of Vireo, and includes statements about, among other things, the value of assets, the amount of liabilities, the designation of certain businesses or assets as “core” or “non-core,” decisions about allocation of capital and other resources, future developments, the future operations, potential market opportunities including the potential effects of the approval of adult-use cannabis in one or more markets, potential opportunities to monetize assets, strengths and strategy of the Company. Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. These statements should not be read as guarantees of future performance or results. Forward-looking information includes statements with respect to the opportunities for the Company to leverage increasing scale to improve sales growth and operating performance; the anticipation that the medical-only state markets in which the Company’s subsidiaries operate could enact recreational-use legislation over the near-to mid-term future; the anticipated benefits of strategic initiatives; the effects of reduction of corporate overhead and SG&A expenses; improvement to unit economics; expansion of retail dispensaries in key markets; and the expectation that such expansion will drive stronger revenue growth, operating margins and free cash flow. Forward-looking information includes both known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release including, without limitation, the impact on the Company’s businesses and financial results of epidemics and pandemics, including the COVID-19 pandemic. Financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to various risks as set out herein. Our actual financial position and results of operations may differ materially from management’s current expectations and, as a result, our revenue and cash on hand may differ materially from the revenue and cash values provided in this news release. Forward-looking information is based upon a number of estimates and assumptions of management, believed but not certain to be reasonable, in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct, including preliminary financial expectations regarding the annualized reduction of corporate overhead and SG&A expenses. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to, risks related to preliminary financial results being subject to the completion of the Company’s financial closing procedures and not being audited or reviewed by the Company’s independent registered public accounting firm; the timing of recreational-use legislation in markets where the Company currently operates; current and future market conditions, including the market price of the subordinate voting shares of the Company; federal, state, local and foreign government laws, rules and regulations, including federal and state laws in the United States relating to cannabis operations in the United States; limited operating history; changes in laws, regulations and guidelines; operational, regulatory and other risks; execution of business strategy; management of growth; difficulty to forecast; conflicts of interest; risks inherent in an agricultural business; liquidity and additional financing; foreign private issuer status and the risk factors set out in the Company’s listing statement dated March 19, 2019, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com.

The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

 

Media Inquiries

Investor Inquiries

Albe Zakes

Sam Gibbons

Vice President, Corporate Communications 

Vice President, Investor Relations

albezakes@vireohealth.com

samgibbons@vireohealth.com 

(267) 221-4800

(612) 314-8995

 

CisionView original content to download multimedia:http://www.prnewswire.com/news-releases/vireo-health-expands-maryland-operations-with-purchase-of-110-000-sq-ft-greenhouse-301080296.html

SOURCE Vireo Health International, Inc.

CHAMPIGNON’S DR. MCINTYRE / CANADIAN RAPID TREATMENT CENTRE OF EXCELLENCE (CRTCE) PUBLISHED IN TWO PEER REVIEWED STUDY JOURNALS

CRTCE’s leading academic footprint facility showing significant outcomes in the arena of psychedelic medicine

VANCOUVER, British Columbia, June 19, 2020 – Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, continues to highlight the scientific merit of its ketamine treatments for Major Depressive Disorder (MDD) while demonstrating rapid onset efficacy and safety of its treatment processes. To this accord, the Company is proud to announce that its Chief Executive Officer, Dr. Roger McIntyre, and the Canadian Rapid Treatment Centre of Excellence (the “CRTCE”) have been recently published in two peer reviewed study journals (the “Peer Reviewed Studies”) focusing on ketamine’s safety, tolerability and effectiveness:

  1. Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: Results from the Canadian rapid treatment center of excellence. Expert Opinion on Drug Safety,1-10. doi:10.1080/14740338.2020.1776699
  2. The Effectiveness of Ketamine on Anxiety, Irritability, and Agitation: Implications for Treating Mixed Features in Adults with Major Depressive or Bipolar Disorder. Bipolar Disorders. doi:10.1111/bdi.12941

The Company invites both current and prospective shareholders to review the Peer Reviewed Studies using applicable databases.

“The publications of data as it relates to ketamine treatment at the CRTCE continues to demonstrate the rapid and robust efficacy of ketamine in persons with depression and related disorders,” said Dr. McIntyre, Champignon’s CEO. “Our data, for the first time in the field of psychiatry, shows that ketamine can improve a person’s ability to function in their role and return to work within a few weeks. The significant efficacy of ketamine at our centre is also matched by stable side-effect profiles, as well as the acceptability of ketamine in people who are benefitting from this novel treatment.”

According to Expertscape.com, Dr. McIntyre is the most recognized researcher in the world as it pertains to depression. Dr, McIntyre developed Canada’s first treatment centre providing rapid onset treatments for persons with mood disorders; The Canadian Rapid Treatment Centre of Excellence (CRTCE). With these recent publications, the CRTCE continues to be the leading, integrated center combining expertise in R&D, clinical research and medicine in depression and related disorders.

About Champignon Brands Inc.

Champignon Brands Inc. (CSE: SHRM) is a research-driven company specializing in the formulation of a suite of medicinal mushrooms health products as well as novel ketamine, anaesthetics and adaptogenic delivery platforms for the nutritional, wellness and alternative medicine industries. Via its vertically integrated alternative medicine product range, Champignon is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes for patients suffering with conditions like depression and post-traumatic stress disorder (PTSD), as well as substance and alcohol use disorders. Under a collaborative research agreement with the University of Miami’s Miller School of Medicine, the Company is conducting preclinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mTBI with PTSD or stand-alone PTSD. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For more information, visit the Company’s website at: https://braxiascientific.com

ON BEHALF OF THE BOARD OF DIRECTORS

Dr. Roger McIntyre
Chief Executive Officer
E: info@braxiascientific.com

FOR INVESTOR INQUIRIES:

Champignon Brands | Storyboard Communications
Investor Relations, Toronto, Canada
Investor Line:  +1 (833) 375-9995 x611
E: champignonbrands@storyboardcommunications.com

Tyler Troup
Circadian Group
E: SHRM@braxiascientific.com

FOR CHAMPIGNON BRANDS FRENCH INQUIRIES:
Remy Scalabrini, Maricom Inc.
E: rs@maricom.ca
T: (888) 585-MARI

The CSE and Information Service Provider have not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. There are no assurances that the business plans for Champignon Brands described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which are available at www.sedar.com.

MindMed To Evaluate Ayahuasca’s Active Ingredient DMT In Phase 1 Clinical Trial Collaboration

MindMed To Evaluate Ayahuasca’s Active Ingredient DMT In Phase 1 Clinical Trial Collaboration

 

Phase 1 Trial to experiment with dosing methods to better understand how humans react to DMT, setting stage for future potential Phase 2a proof of concept trials  

 

Basel, Switzerland June 18, 2020  // MindMed will now pursue N,N-Dimethyltryptamine(DMT), the principally active ingredient inAyahuasca, as part of its R&D collaboration with the University HospitalBasel’s Liechti Lab.  MindMed is providing startup funding for a Phase 1clinical trial testing various intravenous dosing regimens of DMT, expected to begin in Q4 of 2020.

 

DMT is a naturally-occurring psychedelic substance and is the active ingredient used in Ayahuasca ceremonies by indigenousAmazonian shamanic practitioners. DMT causes a rapid onset and offset of action compared to similar psychedelic substances such as psilocybin or LSD.When administered as an Ayahuasca brew, natural substances are mixed with DMT to prolong its experiential effects and slow the metabolism in the human body.

 

MindMedCo-Founder & Co-CEO JR Rahn said: “There is a growing trend in Western society to use Ayahuasca and DMT to facilitate a healing process for one’s mind.  However, there is very limited safety data and clinical trials evaluating DMT as a potential medicine so we are going to double down on understanding the therapeutic opportunity and more effective ways to administer DMT in a controlled setting to achieve this healing process.”

 

Through this Phase 1 clinical trial, MindMed and the Liechti Lab are exploring how DMT can achieve experiential effects similar to Ayahuasca by testing a more controlled intravenous dosing method.

 

There is non-clinical, anecdotal evidence which suggests DMT and Ayahuasca’s experiential effects are powerful healing tools for addiction disorders. The human safety data and associated knowhow gathered in this Phase 1 clinical trial will better enable MindMed’s clinical team to design future potential commercial drug development programs based on DMT sessions.

 

DMTis rapidly metabolized as it enters the bodyif taken orally and therefore it only has a very short duration of action. Incontrast through a continuous intravenous perfusion application the effect islonger but can be stopped rapidly. In order to potentially induce a stable DMT experiencelasting 1-2 hours, an intravenous dosing regimen including a starting dose andthen a maintenance dose will be evaluated in this Phase 1 clinical trial. Thisintravenous administration may also allow therapists to induce and to end anexperiential state safely and more quickly as required.

 

Currently, no study has validly determined the elimination half-life of DMT and other pharmacokinetic parameters and there is limited known data on dosing regimens of pure DMT. This Phase 1 double blind placebo controlled5-period crossover design study will provide a well controlled study setting to illuminate these shortcomings in the current clinical understanding of DMT and pave the way for future Phase 2a proof of concept efficacy studies in various indications.

 

AboutMindMed

Mind Medicine (MindMed) Inc. is a neuro-pharmaceutical company that discovers, develops and deploys psychedelic-inspired medicines to improve health, promote wellness and alleviate suffering. The company’s has initiated or is initiating studies to evaluate potential treatments to help patients withADHD, anxiety, cluster headaches and substance abuse. The MindMed executive team brings extensive biopharmaceutical industry experience to this groundbreaking approach to the development of next-generation psychedelic medicines. MindMed trades on the NEO Exchange under the symbol MMED. MindMed can also be traded in the US under the symbol OTC: MMEDF and in Germany under the symbol DE:BGHM. For more information: www.mindmed.co.

MindMedForward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Mind Medicine (MindMed) Inc. (“MindMed” or the”Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,””expect,” “intend,” “plan,” “believe,””seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying word. These statements concern, and these risks and uncertainties include, among others,MindMed’s and its collaborators’ ability to continue to conduct research and clinical programs (including those discussed in this press release), MindMed’s ability to manage its supply chain, net product sales of products marketed by MindMed and/or its collaborators (collectively, “MindMed’s Products”), and the global economy; the nature, timing, and possible success and therapeutic applications of MindMed’s Products and product candidates and research and clinical programs now underway or planned; the likelihood, timing, and scope of possible regulatory approval and commercial launch of MindMed’s product candidates and new indications for MindMed’s Products; unforeseen safety issues resulting from the administration of MindMed’s Products and product candidates in patients, including serious complications or side effects in connection with the use of MindMed’s Products and product candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict MindMed’s ability to continue to develop or commercializeMindMed’s Products and product candidates; ongoing regulatory obligations and oversight impacting MindMed’s Products, research and clinical programs, and business, including those relating to patient privacy; uncertainty of market acceptance and commercial success of MindMed’s Products and product candidates and the impact of studies (whether conducted by MindMed or others and whether mandated or voluntary) on the commercial success of MindMed’s Products and product candidates; the availability and extent of reimbursement of MindMed’sProducts from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payers and new policies and procedures adopted by such payers; competing drugs and product candidates that may be superior to MindMed’s Products and product candidates; the extent to which the results from the research and development programs conducted by MindMed or its collaborators may be replicated in other studies and lead to therapeutic applications; the ability of MindMed to manufacture and manage supply chains for multiple products and product candidates; the ability of MindMed’s collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labelling, distribution, and other steps related to MindMed’s Products and product candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of MindMed to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto, other litigation and other proceedings and government investigations relating to theCompany and/or its operations, the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on MindMed’s business, prospects, operating results, and financial condition. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by MindMed. MindMed does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.